An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Corcept Therapeutics (NASDAQ: CORT) will unveil its first quarter financial results and share a corporate update on May 1, 2024. A conference call is scheduled for 5:00 p.m. Eastern Time. Participants need to register in advance to receive the dial-in number and access PIN.
Corcept Therapeutics (NASDAQ: CORT) presenterà i risultati finanziari del primo trimestre e fornirà un aggiornamento aziendale il 1 maggio 2024. È prevista una teleconferenza per le 17:00, ora della costa orientale. I partecipanti devono registrarsi in anticipo per ricevere il numero di accesso e il PIN.
Corcept Therapeutics (NASDAQ: CORT) revelará sus resultados financieros del primer trimestre y compartirá una actualización corporativa el 1 de mayo de 2024. Se ha programado una llamada de conferencia para las 5:00 p.m. Hora del Este. Los participantes necesitan registrarse con anticipación para recibir el número de marcado y el PIN de acceso.
코셉트 테라퓨틱스(NASDAQ: CORT)는 2024년 5월 1일에 첫 번째 분기 재무 결과를 발표하고 회사 업데이트를 공유할 예정입니다. 동부 표준시로 오후 5시에 컨퍼런스 콜이 예정되어 있습니다. 참가자는 전화 번호와 접속 핀을 받기 위해 사전에 등록해야 합니다.
Corcept Therapeutics (NASDAQ: CORT) dévoilera ses résultats financiers du premier trimestre et proposera une mise à jour de l'entreprise le 1er mai 2024. Une conférence téléphonique est programmée pour 17h00, heure de l'Est. Les participants doivent s'inscrire à l'avance pour recevoir le numéro d'appel et le code PIN d'accès.
Corcept Therapeutics (NASDAQ: CORT) wird am 1. Mai 2024 die Finanzergebnisse des ersten Quartals bekannt geben und ein Unternehmensupdate teilen. Eine Telefonkonferenz ist für 17:00 Uhr Ostküstenzeit geplant. Teilnehmer müssen sich vorab registrieren, um die Einwahlnummer und die Zugangs-PIN zu erhalten.
Positive
None.
Negative
None.
MENLO PARK, Calif., April 24, 2024 (GLOBE NEWSWIRE) -- Corcept Therapeutics Incorporated (NASDAQ: CORT) today announced it will report first quarter financial results and provide a corporate update on May 1, 2024. The company will also host a conference call that day at 5:00 p.m. Eastern Time (2:00 p.m. Pacific Time).
Conference Call Information
Participants must register in advance of the conference call by clicking here. Upon registering, each participant will receive a dial-in number, and a unique access PIN. Each access PIN will accommodate one caller.
Additionally, a listen-only webcast will be available by clicking here.
A replay of the call will be available on the Investors / Events tab of www.corcept.com.
About Corcept Therapeutics
For over 25 years, Corcept’s focus on cortisol modulation and its potential to treat patients across a wide variety of serious disorders has led to the discovery of more than 1,000 proprietary selective cortisol modulators. Corcept’s advanced clinical trials are being conducted in patients with hypercortisolism, solid tumors, amyotrophic lateral sclerosis (ALS) and non-alcoholic steatohepatitis (NASH). In February 2012, the company introduced Korlym®, the first medication approved by the U.S. Food and Drug Administration for the treatment of patients with Cushing’s syndrome. Corcept is headquartered in Menlo Park, California. For more information, visit www.corcept.com.
leading the field in the discovery of drugs that modulate the effects of cortisol the adverse effects of excess cortisol have been corcept’s focus since the company’s inception. abnormal levels and release of cortisol play a role in a variety of metabolic, oncological, and psychiatric diseases, and we are currently studying a new generation of compounds that may mitigate the effects of excess cortisol. in addition to our work with mifepristone, we have developed over 300 proprietary molecules, advancing the most promising of these to the clinic to see if they can mitigate the effects of excess cortisol and the serious, sometimes life-threatening conditions that may result. all of these compounds competitively block the glucocorticoid receptor (gr), but not the progesterone receptor. scientific literature suggests that competitive gr antagonism may have a role in treating many conditions, including post-traumatic stress disorder, mild cognitive impairment, alzheimer’s disease, alcoholis
